Abagovomab Does Not Prolong Progression-Free Survival in Advanced Ovarian Cancer - ONA
Links shared publicly online about this topic.
- 242total visits
Abagovomab Does Not Prolong Progression-Free Survival in Advanced Ovarian Cancer - ONA
At the American Society of Clinical Oncology’s 2011 Annual Meeting, results of the MIMOSA trial, presented by Jacobus Pfisterer, MD, PhD, from Klinikum Solingen, Germany, and colleagues, demonstrated that abagovomab does not improve progression-free survival in patients with advanced ovarian cancer.
View full resource at oncologynurseadvisor.com
Tags: Cancer, Ovarian Cancer, Women's Health, Doctor
Most Recently Shared on June 4, 2011 at 9:32 pm By:
Abagovomab Does Not Prolong Progression-Free Survival in Advanced Ovarian Cancer http://goo.gl/fb/1PsNY
Advertisement
